AR
ARSUF.US Fagron NV
- Market cap
- USD 1.94B
- P/E
- 18.1x
- P/B
- 2.92x
- ROE
- 16.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ARSUF.US undervalued?
Graham numberARSUF.US trades 53.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fagron NV fundamental analysis
No fundamental analysis for Fagron NV yet.
Fagron NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex …
Full company profileFagron NV financial statements
Fagron NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 422M | 434M | 472M | 535M | 556M | 574M | 684M | 763M | 872M | 952M |
| Gross Profit | 184M | 189M | 208M | 240M | 247M | 247M | 286M | 333M | 396M | 432M |
| Operating Income | 66.9M | 75.9M | 73.2M | 84.4M | 92.4M | 89.9M | 101M | 113M | 134M | 147M |
| EBITDA | - | - | - | - | - | - | 130M | 134M | 158M | 181M |
| Net Income | -20.6M | 46.7M | 42.5M | 41.1M | 59.6M | 61.0M | 69.6M | 70.5M | 80.6M | 91.0M |
| EPS | - | - | - | 0.57 | 0.82 | 0.84 | 0.96 | 0.97 | 1.11 | 1.24 |
| Balance Sheet | ||||||||||
| Total Assets | 868M | 594M | 683M | 801M | 753M | 800M | 971M | 1.01B | 1.08B | 1.24B |
| Total Liabilities | 715M | 409M | 473M | 555M | 495M | 475M | 562M | 539M | 578M | 687M |
| Shareholders' Equity | 153M | 185M | 210M | 246M | 258M | 325M | 409M | 468M | 505M | 556M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 107M | 84.2M | 70.6M | 125M | 133M | 115M | 185M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 67.5M | 84.2M | 73.3M | 77.2M | 93.0M | 78.4M | 109M | 125M | 110M | 155M |
| Capital Expenditure | 14.8M | 10.0M | 15.7M | 22.2M | 18.4M | 20.7M | 18.5M | 38.5M | 40.8M | 30.6M |
| Free Cash Flow | - | - | - | 55.0M | 74.5M | 57.7M | 91.0M | 86.2M | 69.1M | 125M |
| Ratios | ||||||||||
| ROE | -13.5% | 25.2% | 20.3% | 16.7% | 23.1% | 18.7% | 17.0% | 15.1% | 15.9% | 16.4% |
| ROA | -2.4% | 7.9% | 6.2% | 5.1% | 7.9% | 7.6% | 7.2% | 7.0% | 7.4% | 7.3% |
| Net Profit Margin | -4.9% | 10.8% | 9.0% | 7.7% | 10.7% | 10.6% | 10.2% | 9.2% | 9.2% | 9.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fagron NV dividends
- Dividend yield
- -
- Forward dividend
- 0.40 USD
- Payout ratio
- 28.6%
- Ex-dividend date
- May 19, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 26.0M | 0.36 | 28.6% |
| 2024 | EUR 21.0M | 0.29 | 26.1% |
| 2023 | EUR 18.3M | 0.25 | 25.9% |
| 2022 | EUR 14.6M | 0.20 | 20.9% |
| 2021 | EUR 13.0M | 0.18 | 21.4% |
| 2020 | EUR 5.77M | 0.08 | 9.7% |
| 2019 | USD 8.61M | 0.12 | 21.0% |
| 2018 | USD 7.17M | - | 16.9% |
| 2017 | USD 7.17M | - | 15.4% |
| 2016 | USD 7.17M | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 269:250 on Aug 16, 2016.
Who owns Fagron NV
- Insiders 0.30%
- Institutions 71.94%
- Public & others 27.76%
- Shares outstanding 73.4M
- Free float 65.9M
Fagron NV company profile
- Company name
- Fagron NV
- Ticker
- ARSUF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,880
- Fiscal year end
- December
- Address
- Venecoweg 20A, Nazareth, Belgium, 9810
- Phone
- 32 800 128 80
- Website
- fagron.com
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Fagron NV management
5- Mr. Rafael PadillaCEO & Executive Director · born 1978
- Ms. Karin de JongCFO & Executive Director · born 1979
- Ms. Vera BakkerChief Operating Officer · born 1972
- Ignacio ArtolaGlobal Head of Investor Relations
- Kenneth BonnellGlobal Head of Quality